Press Releases
-
Verana Health and the American Academy of Ophthalmology Launch the Verana Research Network, an IRIS Registry Initiative
Partnership seeks to increase clinical trials access, accelerate recruitment, and advance ophthalmic research
Dec 6, 2022
-
PHASTAR Launches Pro-Bono Scheme for Charities
PHASTAR, a global specialist biometrics contract research organization (CRO), has announced the launch of a pro-bono scheme to give charities access to its volunteer statisticians, data scientists, data managers and programmers at no cost.
Dec 6, 2022
-
Recipharm announces extension of commercial manufacturing to support RedHill Biopharma’s Talicia® to 2026
Global contract development and manufacturing organization (CDMO) Recipharm, today announced an extension of the ongoing commercial manufacturing of RedHill Biopharma’s (Nasdaq: RDHL) drug, Talicia® for the treatment of H. pylori infection, to 2026.
Dec 5, 2022
-
New startup Graegis Pharmaceuticals to prevent skin and mucosa side effects of radiotherapy
Graegis Pharmaceuticals has announced its plan to start proof-of-concept clinical trials in 2023 in the prevention of radiation-induced dermatitis and mucositis.
Dec 5, 2022
-
IDDI (International Drug Development Institute) Appoints Linda Danielson as its new Chief Executive Officer.
IDDI appoints new CEO, to strengthen the organization's position to support and serve US and EU clients.
Jul 6, 2022
-
Lonza’s API Mid-Scale Manufacturing Facility Expansion in Nansha Enters Commercial Operation
-
MIB Agents Awards $100,000 Grant for Pediatric Osteosarcoma Research at MD Anderson
MIB Agents, a leading pediatric osteosarcoma nonprofit dedicated to Making It Better for its community of patients, caregivers, doctors, and researchers, has awarded a $100,000 research grant to Andy Livingston, M.D., a clinician and researcher in Sarcoma Medical Oncology and in Pediatric Oncology at The University of Texas MD Anderson Cancer Center. Ann Graham, Founder and Executive Director of MIB Agents, and Christina Ip-Toma, MIB Agents’ Director of Scientific Programs, presented the award to Dr. Livingston on Dec. 1 in Houston.
Dec 4, 2022
-
The Mobile Health/Central Lab Interface, an opportunity for DCT efficiency
The Mobile Health/Central Lab Interface, an opportunity for DCT efficiency How streamlining relations between central labs and mobile health providers can get the most from hybrid and decentralised clinical trials
Nov 30, 2022
-
Emplicure AB and Quotient Sciences Announce an Integrated Manufacturing and Clinical Testing Partnership for Emplicure’s First Clinical Pharmacokinetic Study for EMPLI03
Quotient Sciences, a global drug development and manufacturing accelerator, today announced a partnership with Emplicure, a Swedish pharmaceutical company focused on chronic pain and abuse-deterrent formulations.
Nov 30, 2022
-
Upgrading to FFP3 face masks in hospitals could save the NHS £360m a year and help slash patient waiting lists
The NHS could save up to £360M per year by using FFP3 face masks and the NHS already has a large stockpile of these masks so there is no current need to purchase more. Independent studies commissioned by PPE manufacturer Globus Group and carried out by York Economic Health Consortium and Vital Economics confirm that these masks may be better at preventing respiratory infection and resulting staff days off.
Nov 30, 2022
-
Scipio bioscience Announces a Single-Cell Grant Program for Four Researchers to Receive a Complete 3′ scRNA-seq Solution Valued up to US$30,000
Scipio bioscience has announced a grant program for researchers to receive a complete 3′ scRNA-seq solution valued at up to US$30,000.
Nov 30, 2022
-
CD ComputaBio Introduces PyMOL Software for Bioinformatics Analysis
-
Pronalyse’s Fusion Protein Characterization Service Aids in the Drug Development Process
-
Creative Proteomics Lipidomics Launches Ceramides Analysis Service
-
Creative Proteomics Metabolomics Unveils Drug-Resistant Metabolomics Research Service
-
Dolomite Bio launches RNAdia 2.0 Reagent Kit – Fast, Easy, Robust
Dolomite Bio has announced the launch of the RNAdia 2.0 reagent kit for single cell research. At a significantly lower cost compared to competitor reagents the new and improved RNAdia 2.0 kit alleviates that stress, allowing researchers to focus on what is important, doing more and discovering more.
Nov 29, 2022
-
UK Supplier expands to provide Chemically Defined & Serum-Free Cell Media Solutions for the Cell and Gene Therapy Industry
BioPharma Dynamics has announced the expansion of its extensive portfolio to offer a range of chemically defined T-Cell Media, DMSO-Free Cryopreservation Solutions, and Recombinant Growth Factors, for the Cell & Gene Therapy market.
Nov 29, 2022
-
Biopharma PEG Develops PEG Products For Click Chemistry
-
Huateng Pharma Supplies Semaglutide Intermediates Against Type 2 Diabetes
-
Genezen appoints Chief Commercial Officer to Executive Leadership Team
Genezen appoints Jeff Whitmore as CCO
Nov 28, 2022